An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

  • Interventional
  • Recruiting
  • NCT01968109
Eligibility Details Visit Clinicaltrials.gov

A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery. The following tumor types are included in this study: Non-Small Cell Lung Cancer (NSCLC), gastric cancer, hepatocellular carcinoma, renal cell carcinoma, bladder cancer, squamous cell carcinoma of the head and neck, and melanoma, that have NOT previously been treated with immunotherapy. NSCLC and melanoma that HAVE previously been treated with immunotherapy.

Gender
All

Age Group
12 Years and up

Accepting Healthy Volunteers?
No

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

        Inclusion Criteria:

         - For Dose escalation: subjects with cervical, ovarian, bladder and colorectal cancer (CRC), head and neck, gastric and hepatocellular cancer naive to immuno-oncology agents; 1st line melanoma and 1st line/2nd line NSCLC; Renal Cell Carcinoma naive to IO; NSCLC progressing while on or after therapy with anti-PD1/anti-PDL-1 and melanoma subjects progressed while-on or after treatment with anti-PD1 or anti-PDL1 with or without anti-CTLA-4.

         - For Dose Expansion: all of the above in escalation except for cervical, ovarian, and CRC

         - Progressed, or been intolerant to, at least one standard treatment regimen, except for subjects in 1st line cohorts.

         - ECOG performance status between 0 and 2

         - At least 1 lesion with measurable disease at baseline

         - Availability of an existing tumor biopsy sample (and consent to allow pre-treatment tumor biopsy)

        Exclusion Criteria:

         - Primary central nervous system (CNS) tumors or solid tumors with CNS metastases as the only site of active disease

         - Autoimmune disease

         - Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent

         - Uncontrolled CNS metastases

At a Glance

National Government IDNCT01968109

IRB#IRB13-0936

Lead SponsorBristol-Myers Squibb

Lead PhysicianThomas F. Gajewski

Collaborator(s)N/A

EligibilityAll
12 Years and up
Recruiting